Porownywarka

GHRP-2 vs GHRP-6 side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

GHRP-2GHRP-6

Udostępnij porównanie peptydów

Wlasciwosc	GHRP-2	GHRP-6
Kategoria	Hormon wzrostu	Hormon wzrostu
Znany tez jako	Growth Hormone Releasing Peptide 2, Pralmorelin, KP-102	Growth Hormone Releasing Peptide 6, SKF-110679
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Approved in some countries for growth hormone deficiency diagnosis; not FDA approved and listed as FDA Category 2 restricted in the source. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical/investigational; source notes FDA Category 2 compounding restriction concerns Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Growth hormone release, muscle gain, recovery	Appetite stimulation, muscle building, GH release
Jak dziala	GHRP-2 is reported to act at GHS-R1a, the ghrelin or growth hormone secretagogue receptor. The supplied evidence places the relevant signaling in pituitary and hypothalamic pathways and links receptor activation to a pulsatile release of growth hormone. The source also notes that appetite and other hormonal effects may still occur because the ghrelin system is involved.	GHRP-6 is reported to act as an agonist at GHS-R1a, the growth hormone secretagogue receptor associated with ghrelin biology. The source links receptor activation in pituitary and hypothalamic pathways to growth hormone pulse release. It also notes that GHS-R1a involvement in NPY/AgRP appetite circuitry may contribute to GHRP-6's prominent hunger effect, and that higher doses may raise cortisol and prolactin.
Typowe dawkowanie	100-300 mcg 2-3x daily · 2-3x daily	100-300 mcg 2-3x daily · 2-3x daily · Subcutaneous injection
Dawkowanie z badań	100-300 mcg per injection · 8-12 weeks · Subcutaneous injection	100-300 mcg per injection · 8-12 weeks · Subcutaneous injection, reported as fasted
Typowy czas trwania	8-12 weeks	8-12 weeks
Podanie	Slow intravenous injection for the approved Japanese diagnostic test; subcutaneous administration is investigational.	Subcutaneous injection, reported with fasted timing
Timing	Before bed or morning while fasted Empty-stomach timing reported	Reported timing: fasted morning use or before bed Source reports empty-stomach or fasted timing
Poziom dowodów	Badania kliniczne	Badania kliniczne
Mozliwe skutki uboczne	Increased appetite (Reported as less pronounced than with GHRP-6 in the source.) Water retention Fatigue +5 więcej Headache Nausea Possible cortisol and prolactin elevation (Source notes this as a concern, reportedly less than with GHRP-6.) Possible histamine release (Source advises caution in the context of MCAS or histamine sensitivity.) Active malignancy contraindication (Listed as contraindicated with active malignancies in the source.)	Significant hunger increase (Source describes this as especially pronounced among GHRPs.) Water retention (Reported by source; severity not quantified.) Elevated cortisol levels (Source notes this concern, particularly at higher doses.) +6 więcej Elevated prolactin levels (Source notes this concern, particularly at higher doses.) Flushing (Reported by source; severity not quantified.) Nausea (Reported by source; severity not quantified.) Headache (Reported by source; severity not quantified.) Possible histamine release (Source advises caution for MCAS or histamine sensitivity, but does not quantify risk.) Limited long-term safety data (Source indicates long-term safety evidence is limited.)
Podsumowanie researchu	The source describes the strongest human evidence for GHRP-2 as its diagnostic role rather than wellness or body-composition use. It reports phase II development and approval in Japan as pralmorelin for growth hormone deficiency testing, including pediatric short-stature contexts. It also cites a human pharmacology study in ten male volunteers where GHRP-2 and metabolite AA-3 were detected in urine after intravenous administration, with anti-doping relevance because the compound is banned in sport. The source does not present solid controlled-trial support for marketed anti-aging, recovery, or body-composition claims.	The supplied source describes GHRP-6 as a research tool studied in humans, mainly for laboratory or diagnostic investigation of growth hormone release rather than as a validated therapeutic intervention. It notes early research showing growth hormone release, and connects investigation of this peptide class to the later identification of ghrelin. A cited 2013 pharmacokinetic study in nine healthy men is summarized as finding very low oral bioavailability and an elimination half-life of about 2.5 hours. The source states that popular fitness-related outcome claims such as muscle gain, fat loss, and healing lack controlled human outcome-trial support, and it reiterates that GHRP-6 is not FDA or EMA approved.
Referencje	PubMed PubMed +1 więcej Wiley Online Library	Źródło Źródło +1 więcej Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

GHRP-2

GHRP-6

Kategoria

Hormon wzrostu

Znany tez jako

Growth Hormone Releasing Peptide 2, Pralmorelin, KP-102

Growth Hormone Releasing Peptide 6, SKF-110679

Zatwierdzony przez FDA

Nie

Status kliniczny

Approved in some countries for growth hormone deficiency diagnosis; not FDA approved and listed as FDA Category 2 restricted in the source.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical/investigational; source notes FDA Category 2 compounding restriction concerns

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Growth hormone release, muscle gain, recovery

Appetite stimulation, muscle building, GH release

Jak dziala

GHRP-2 is reported to act at GHS-R1a, the ghrelin or growth hormone secretagogue receptor. The supplied evidence places the relevant signaling in pituitary and hypothalamic pathways and links receptor activation to a pulsatile release of growth hormone. The source also notes that appetite and other hormonal effects may still occur because the ghrelin system is involved.

GHRP-6 is reported to act as an agonist at GHS-R1a, the growth hormone secretagogue receptor associated with ghrelin biology. The source links receptor activation in pituitary and hypothalamic pathways to growth hormone pulse release. It also notes that GHS-R1a involvement in NPY/AgRP appetite circuitry may contribute to GHRP-6's prominent hunger effect, and that higher doses may raise cortisol and prolactin.

Typowe dawkowanie

100-300 mcg 2-3x daily · 2-3x daily

100-300 mcg 2-3x daily · 2-3x daily · Subcutaneous injection

Dawkowanie z badań

100-300 mcg per injection · 8-12 weeks · Subcutaneous injection

100-300 mcg per injection · 8-12 weeks · Subcutaneous injection, reported as fasted

Typowy czas trwania

8-12 weeks

Podanie

Slow intravenous injection for the approved Japanese diagnostic test; subcutaneous administration is investigational.

Subcutaneous injection, reported with fasted timing

Timing

Before bed or morning while fasted

Empty-stomach timing reported

Reported timing: fasted morning use or before bed

Source reports empty-stomach or fasted timing

Poziom dowodów

Badania kliniczne

Mozliwe skutki uboczne

Increased appetite (Reported as less pronounced than with GHRP-6 in the source.)
Water retention
Fatigue

+5 więcej

Headache
Nausea
Possible cortisol and prolactin elevation (Source notes this as a concern, reportedly less than with GHRP-6.)
Possible histamine release (Source advises caution in the context of MCAS or histamine sensitivity.)
Active malignancy contraindication (Listed as contraindicated with active malignancies in the source.)

Significant hunger increase (Source describes this as especially pronounced among GHRPs.)
Water retention (Reported by source; severity not quantified.)
Elevated cortisol levels (Source notes this concern, particularly at higher doses.)

+6 więcej

Elevated prolactin levels (Source notes this concern, particularly at higher doses.)
Flushing (Reported by source; severity not quantified.)
Nausea (Reported by source; severity not quantified.)
Headache (Reported by source; severity not quantified.)
Possible histamine release (Source advises caution for MCAS or histamine sensitivity, but does not quantify risk.)
Limited long-term safety data (Source indicates long-term safety evidence is limited.)

Podsumowanie researchu

The source describes the strongest human evidence for GHRP-2 as its diagnostic role rather than wellness or body-composition use. It reports phase II development and approval in Japan as pralmorelin for growth hormone deficiency testing, including pediatric short-stature contexts. It also cites a human pharmacology study in ten male volunteers where GHRP-2 and metabolite AA-3 were detected in urine after intravenous administration, with anti-doping relevance because the compound is banned in sport. The source does not present solid controlled-trial support for marketed anti-aging, recovery, or body-composition claims.

The supplied source describes GHRP-6 as a research tool studied in humans, mainly for laboratory or diagnostic investigation of growth hormone release rather than as a validated therapeutic intervention. It notes early research showing growth hormone release, and connects investigation of this peptide class to the later identification of ghrelin. A cited 2013 pharmacokinetic study in nine healthy men is summarized as finding very low oral bioavailability and an elimination half-life of about 2.5 hours. The source states that popular fitness-related outcome claims such as muscle gain, fat loss, and healing lack controlled human outcome-trial support, and it reiterates that GHRP-6 is not FDA or EMA approved.

Referencje

+1 więcej

+1 więcej

Pełny profil